Display options
Cite
Gogia A, Nair S, Arora S, et al. Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India. Front Oncol. 2021;11:770747doi: 10.3389/fonc.2021.770747.
Gogia, A., Nair, S., Arora, S., Kumar, L., Sharma, A., Gupta, R., Biswas, A., & Mallick, S. (2021). Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India. Frontiers in oncology, 11770747. https://doi.org/10.3389/fonc.2021.770747
Gogia, Ajay, et al. "Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India." Frontiers in oncology vol. 11 (2021): 770747. doi: https://doi.org/10.3389/fonc.2021.770747
Gogia A, Nair S, Arora S, Kumar L, Sharma A, Gupta R, Biswas A, Mallick S. Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India. Front Oncol. 2021 Dec 02;11:770747. doi: 10.3389/fonc.2021.770747. eCollection 2021. PMID: 34926277; PMCID: PMC8675100.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2021 Dec 02;11:770747. doi: 10.3389/fonc.2021.770747. eCollection 2021.

Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India.

Frontiers in oncology

Ajay Gogia, Sukesh Nair, Shalabh Arora, Lalit Kumar, Atul Sharma, Ritu Gupta, Ahitagni Biswas, Saumyaranjan Mallick

Affiliations

  1. Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
  2. Department of Laboratory Oncology, All India Institute of Medical Sciences, New Delhi, India.
  3. Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India.
  4. Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.

PMID: 34926277 PMCID: PMC8675100 DOI: 10.3389/fonc.2021.770747

Abstract

INTRODUCTION: There is a scarcity of data from India on the impact of cell of origin (COO) on outcomes of diffuse large B-cell lymphoma (DLBCL). This study was conducted to evaluate the impact of COO on outcomes of DLBCL patients treated with uniform rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (RCHOP) protocol.

MATERIALS AND METHODS: This retrospective analysis included patients who received uniform RCHOP chemoimmunotherapy during the study period (2014-2020) at the Department of Medical Oncology at All India Institute of Medical Sciences (AIIMS), New Delhi, India. The patients were classified as germinal center B-cell like (GCB) or activated B-cell (ABC) type using the Hans classification.

RESULTS: Four hundred seventeen patients with median age of 48 years (range, 18-76) and a male-female ratio of 2:1 were included in the analysis. B symptoms and bulky disease were seen in 42.9% and 35.5%. Extranodal involvement was seen in 50.8% of cases. ECOG performance status (0-2) was present in 65%, and 51% presented with advanced disease. GCB subtype was seen in 43%, and 47% were ABC type. Low- and intermediate-risk international prognostic index (IPI) score was seen in 76% of cases. The overall response rate to RCHOP was 85.8%, including a complete response rate of 74.8%. After a median follow-up of 30 months, the 3-year event-free survival (EFS) and overall survival (OS) were 80% and 88%, respectively. The presence of B symptoms and poor ECOG performance status (3-4) was associated with inferior CR rate. Low albumin (

CONCLUSIONS: Cell of origin for DLBCL has no impact on CR, EFS, and OS if patients are appropriately treated with standard doses and frequency of RCHOP. RCHOP is well tolerated in our patients, and results are comparable with the Western data.

Copyright © 2021 Gogia, Nair, Arora, Kumar, Sharma, Gupta, Biswas and Mallick.

Keywords: CHOP (R-CHOP); India; cell of origin; diffuse large B-cell lymphoma (DLBCL); rituximab; survival

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publication Types